The developers of the Russian vaccine Sputnik V have said they will shortly offer booster doses that will combat the Delta variant of COVID.
These vaccines will be offered to other vaccine manufacturers. While vaccine manufacturers across the globe have differences in opinions over administering doses of different COVID-19 vaccines, Sputnik V producers have extensively advocated the idea of the ‘vaccine cocktail’.
Gamaleya Institute of Epidemiology and Microbiology, the maker of Sputnik V, has asserted that different adenoviral vectors Ad5 & Ad26 for two vaccine shots will result in greater efficacy than using the same vector for two shots.
“Heterogeneous boosting helped Sputnik V reach its outstanding efficacy confirmed by real-world studies. This approach gained global recognition as a weapon vs coronavirus mutations that cause new lockdowns & defer victory over COVID,” Sputnik V manufacturer stated on Twitter.
While world leaders seem reluctant to take Sputnik V, Russian President, Vladimir Vladimirovich Putin hits out at nations for not approving Sputnik V, calling it ‘politically motivated’
Earlier, a few days back, Russia’s Direct Investment Fund (RDIF) and Gamalaya Institute had carried out a study and discovered that Sputnik V was extremely effective in neutralizing the noxious COVID Delta variant of COVID-19, which is highly transmissible has now mutated further to form the ‘Delta plus’ variant, however, scientists assure the public that there is no cause for concern in India yet.
Last month, the World Health Organisation had stamped the B.1.617.2 strain as the ‘Delta’ variant of COVID-19 which was recognized as one of the dangerous operators of the calamitous second wave of Coronavirus, which particularly hit India hard.
The Delta plus variant has been formed due to a mutation in the Delta or B.1.617.2 variant, first identified in India, identified to be the primary cause of the deadly second wave. Though there is no indication yet of the severity of the disease due to the new variant, Delta plus is found to be resistant to the monoclonal antibody cocktail treatment for COVID-19 recently approved in India.
At this time, Sputnik V is one of the three vaccines in the world, the other two being Pfizer and Moderna, to have an efficacy of over 90 percent against coronavirus disease.
Sputnik V released a series of tweets detailing more information about the vaccine, which is shared below:
BREAKING: #SputnikV will soon offer a booster shot, adjusted to work against the Delta variant of coronavirus, first detected in India, to other vaccine manufacturers. Below are the highlights of Sputnik V’s pioneering role in developing vaccine cocktails.
— Sputnik V (@sputnikvaccine) June 17, 2021
Sputnik V was the 1st #COVID vaccine cocktail in the world when created by the Gamaleya Center in April 2020. It uses heterogeneous boosting with 2 shots by 2 different adenoviral vectors Ad5 & Ad26 as we explained in this op-ed published nearly a year agohttps://t.co/45U5XAp3iS
— Sputnik V (@sputnikvaccine) June 17, 2021
Moreover, the vaccine developed by the Gamaleya Center against the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2019, even before the novel coronavirus outbreak, was also a vaccine cocktail.
?https://t.co/QnhOYRt4Uf— Sputnik V (@sputnikvaccine) June 17, 2021
Heterogeneous boosting helped Sputnik V reach its outstanding efficacy confirmed by real-world studies. This approach gained global recognition as a weapon vs coronavirus mutations that cause new lockdowns & defer victory over COVID.
?https://t.co/qK211gKEtB— Sputnik V (@sputnikvaccine) June 17, 2021
Sputnik V was the 1st vaccine maker to offer joint clinical trial of a vaccine cocktail on Nov 23, 2020. This offer was accepted. Soon after other developers started exploring this approach. We ask the media to acknowledge our leading role.https://t.co/YvCckfhnYq
— Sputnik V (@sputnikvaccine) June 17, 2021
We’ve always said that vaccine cocktails are the way of the future. We offer all vaccine makers to use our shot in cocktails against #COVID mutations. As early as November 2020 we talked about advantages of heterogeneous boosting on Twitter. https://t.co/Cp7yj9hG7U
— Sputnik V (@sputnikvaccine) June 17, 2021